You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. Hepatitis

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C

  • Technology appraisal guidance
  • Reference number: TA106
  • Published:  23 August 2006
  • Last updated:  27 November 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Appraisal Committee members and NICE project team
  • 8 Sources of evidence considered by the Committee
  • Appendix A Detail on criteria for audit of the use of peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C

6 Recommendations for further research

6.1

Research is needed on the quality of life and progression rates among a random sample of people with mild disease compared with people presenting for treatment. This research might also include retrospective studies of progression among people who have already been diagnosed for reasons other than having symptoms of the disease.


Next page 7 Appraisal Committee members and NICE project team Previous page 5 Implementation
Back to top